Pedley Provides 340B Update but Avoids Contract Pharmacy Controversy

Due to litigation, 340B program director Rear Adm. Krista Pedley could say little about the drug discount program during yesterday’s 340B Coalition virtual summer conference.
Rear Adm. Krista Pedley, Director of the U.S. Health Resources and Services Administration’s (HRSA) Office of Pharmacy Affairs, gave a brief update on the 340B program during yesterday’s 340B Coalition virtual summer conference. She explained that “due to current litigation
Read More »

House GOP Starts Crafting Health Care Bills in Anticipation of Retaking Majority

U.S. Rep. Brett Guthrie (R-Ky.) is a co-leader of the House GOP's Healthy Future Task Force. He is also the ranking GOP member on the House committee overseeing 340B.
The top Republicans on two U.S. House health subcommittees are leading a party effort to “craft legislative proposals that Republicans can advance after retaking the majority” in the November 2022 midterm elections. It is not known whether the group will
Read More »

340B Program Flexibilities to Continue As COVID-19 Emergency Extended

HHS Secretary Xavier Becerra this week extended the COVID-19 public health emergency until mid-October.
U.S. Health and Human Services (HHS) Secretary Xavier Becerra on Monday extended the COVID-19 national public health emergency (PHE) for another 90 days, to Oct. 17. The move extends 340B program flexibilities implemented during the pandemic’s early days.
Read More »

Biden Administration’s Proposal to Retain 340B Hospital Drug Payment Cuts Draws More Fire

Groups whose members include 340B hospitals yesterday slammed CMS for proposing to continue deep drug payment cuts to 340B hospitals.
Several groups whose members or clients include 340B hospitals yesterday slammed the Biden administration’s decision to continue the Trump administration’s huge cut in Medicare Part B reimbursement for hospitals’ 340B purchased drugs. The American Hospital Association (AHA) has not, so
Read More »

One-Fourth of 340B DSH Hospitals at Risk of Losing Eligibility Due to Pandemic, Analysis Finds

Many hospitals reduced inpatient admissions during the COVID-19 pandemic. 340B hospitals now fear that this could cause them to lose their eligibility for 340B drug discounts due to changes in patient mix.
Roughly one out of four 340B disproportionate share (DSH) hospitals could lose their eligibility for 340B drug discounts due to COVID-19 pandemic-related changes in patient mix, an analysis of hospital Medicare cost reports for 2019 and 2020 shows. About one
Read More »

Judge Consolidates Arguments in Two 340B Contract Pharmacy Lawsuits

A federal district judge will hold a joint hearing in October on drug makers’ Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.
A federal district judge will hold a joint hearing in October on drug makers’ Novartis and United Therapeutics’ (UT) lawsuits challenging the government’s findings in May that the two companies’ 340B contract pharmacy policies are unlawful.
Read More »

United Therapeutics Fleshes Out its 340B Contract Pharmacy Legal Arguments

United Therapeutics told a judge on Friday that the government’s position that the company's 340B contract pharmacies are illegal “contravenes the plain text” of the 340B statute.
The government’s position that United Therapeutics’ (UT) restrictions on 340B contract pharmacies are illegal “contravenes the plain text” of the 340B statute, the drug company told a federal district judge on Friday.

Please Login or Become

Read More »

In Surprise Move, Biden Administration Proposes Keeping Trump’s Nearly 30% Cut in 340B Hospitals’ Drug Reimbursement

The U.S. Centers for Medicare & Medicaid Services (CMS) said today it proposes to continue a nearly 30% reduction in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs.

The Biden administration said today it proposes to continue a nearly 30% reduction in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs.

The Trump administration implemented the payment reduction in January 2018. Hospital groups say it costs affected 340B hospitals

Read More »

Key Congressional Committee Urges HRSA to Fine Drug Makers Over 340B Contract Pharmacy Denials

U.S. House appropriators are encouraging HRSA to use fines and "any available measures" to hold drug manufacturers accountable for withholding 340B drug discounts.
The U.S. House Appropriations Committee is pleased with the U.S. Health Resources and Services Administration (HRSA) for challenging six drug makers’ denials of 340B pricing when covered entities use contract pharmacies, the committee said in a report released yesterday. It
Read More »
Generic selectors
Exact matches only
Search in title
Search in content